ZUG, Switzerland--(BUSINESS WIRE)--Galderma will present updates from across its broad dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7 ...
Results from the Phase 3 CORALreef Lipids and HeFH trials of investigational oral PCSK9 inhibitor enlicitide decanoate will be presented for the first time Presentations across hypercholesterolemia ...
This study will examine the U.S. Geological Survey's Mineral Resources Program (MRP) science portfolio to address how it needs to evolve to meet current and future U.S. mineral resources data and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results